The negative correlations between CDK1 and the ESTIMATEScore, the ImmuneScore, and the StromalScore, as well as the positive correlations between CDK1 expression and MDSC infiltration, MSI, and TMB across multiple tumors, suggest that CDK1 may potentially serve as a novel and effective target for cancer immunotherapy. The gene discussed is CDK1; the disease is cancer.